Common adverse reactions in patients treated with dalbavancin were nausea (5.5%), headache (4.7%), and diarrhea (4.4%). Adverse reactions lasted for a median of 4 days.1 Proportion of patients in clinical trials that discontinued treatment due to adverse events was 3% for dalbavancin and 2.8% for the comparator treatment.1